AbCellera Biologics Inc (NASDAQ:ABCL) currently has a daily average trading volume of 1.74M but it saw 1649522 shares traded in last market. With a market cap of 736.68M USD, the company’s current market price of $2.50 came rising about 0.40 while comparing to the previous closing price of $2.49. In past 52 weeks, the stock remained buoying in the range of price level as high as $6.05 and as low as $2.34. In the recent trading on the day, stock has struck highest price mark of $2.41 while lowest mark touched by it was $2.5291.
Taking a look at 20-day trading activity of AbCellera Biologics Inc (ABCL) gives us an average price of $2.58, while its current price level is -58.71% below from 52-week high level whereas it is 7.07% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.61 while that of 200 days or SMA-200 reads an average of $3.85. A closer look into the stock’s movement over the week reveals that its volatility is standing at 4.83% during that period while stretching the period over a month that increases to 5.19%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 45.01 which implies that the stock is in neutral territory.
The Benchmark Company upgraded its recommendation for the stock as a “Buy” from “Hold” on February 22, 2024 while assigning a price target of $9. KeyBanc Capital Markets issued its recommendations for the stock as it initiated the price target for the stock is $6.
Over the week, ABCL’s stock price is moving 0.81% up while it is -7.06% when we observe its performance for the past one month. Year-to-date it is -56.22% down and over the past year, the stock is showing a downside performance of -44.69%.
Currently, AbCellera Biologics Inc’s total number of outstanding shares is 290.82M. Company’s return on investment (ROI) stands at -13.02% and return on equity (ROE) at -13.30%. Stock’s beta reads 0.37. Stock has a price to book (P/B) ratio of 0.66 while price to sale or P/S ratio amounts to 22.28. Its return on asset (ROA) is -10.39% on average.
